Rapid engraftment of mast cells of donor origin in a case of acute myeloid leukemia with mast cell leukemia after allogeneic stem cell transplantation
نویسندگان
چکیده
منابع مشابه
A Case of Systemic Mastocytosis Associated with Acute Myeloid Leukemia Terminating as Aleukemic Mast Cell Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
In up to 40% of systemic mastocytosis (SM) cases, an associated clonal hematological non-mast cell lineage disease such as AML is diagnosed before, simultaneously with, or after the diagnosis of SM. A 40-yr-old man was diagnosed with AML with t(8;21)(q22;q22). Mast cells were not noted at diagnosis, but appeared as immature forms at relapse. After allogeneic hematopoietic stem cell transplantat...
متن کاملPreliminary Results of Allogenic Hematopoietic Stem Cell Transplantation of non-M3 Acute Myeloid Leukemia
Background: Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) is used as treatment of choice for patients with acute myeloid leukemia (AML). We aimed to evaluate the prognostic factors in 2-year overall survival of patients with non-M3 AML who underwent allogenic HSCT. Methods: This is a Cross sectional retrospective study. Demographic data and study of variables such as age...
متن کاملeffects of agvhd and cgvhd on survival rate in patients with acute myeloid leukemia after allogeneic stem cell transplantation.
background: allogeneic hematopoietic stem cell transplantation (hsct) is a curative treatment option for many patients with acute myeloid leukemia (aml); however, it can lead to complications of graft-versus-host-disease (gvhd) which can affect the quality of life and overall survival. the aim of this study was to assess the effects of both acute and chronic gvhd on survival rate in patients wi...
متن کاملAllogeneic stem cell transplantation in acute myeloid leukemia
Allogeneic hematopoietic stem cell transplantation (alloSCT) has been established as a powerful treatment modality in acute myeloid leukemia (AML) in first or subsequent remission. Although alloSCT effectively prevents relapse, non-relapse mortality (NRM) associated with the procedure may counterbalance that beneficial effect. As a result, alloSCT generally is restricted to patients with a rela...
متن کاملMast Cell Leukemia with Ascites and Multiple Organs Damage
Mast Cell Leukemia (MCL), a rare subtype of systemic mastocytosis is defined by bone marrow involvement as atypical and aleukemic mast cells, if more than 20% and less than 10% of peripheral WBCs are mast cells, respectively. We met a case of aleukemic MCL presenting with anemia and ascites for 2 years, referred for BM evaluation, suspicious of leukemia. Our findings included BM involveme...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Bone Marrow Transplantation
سال: 2003
ISSN: 0268-3369,1476-5365
DOI: 10.1038/sj.bmt.1704098